Beyonttra (Acoramidis)

Beyonttra (acoramidis) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

Recommended Dosage:
The recommended dosage of Beyonttra is 712 mg taken orally twice daily, with or without food. Tablets are intended to be swallowed whole and must not be cut, crushed, or chewed. If a dose is missed, patients should take the next scheduled dose at the regular time and should not take two doses together to make up for the missed dose.
Patients are advised to follow their healthcare provider’s instructions carefully to ensure safe and effective treatment.

• Patients receiving treatment with Beyonttra (acoramidis) should undergo regular monitoring by their clinician, as worsening heart-related symptoms such as swelling, shortness of breath, or fatigue may still occur despite ongoing treatment for transthyretin amyloid cardiomyopathy.
• Let your doctor know about all medicines, supplements, or herbal products before starting this treatment, because certain medicines may interact with treatment and could affect how the treatment works or increase the risk of undesired side effects.
• The safety of this therapeutic drug during pregnancy or breastfeeding has not been fully established. Women who are pregnant, looking for pregnancy, or breastfeeding should discuss all the risks and benefits with their treating clinician before treatment.
• Patients with severe liver or kidney impairment should use Beyonttra cautiously, as limited clinical evidence is available in these groups. Dose adjustments or additional monitoring may be required depending on the patient’s overall medical condition.
• Although this therapeutic drug is generally well tolerated, some patients may experience mild side effects such as diarrhea, stomach discomfort, or dizziness. Persistent or worsening symptoms should be reported to a doctor for further medical evaluation.

What documents are required to import Beyonttra to India?

Beyonttra (acoramidis) may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a qualified doctor
• The patient’s diagnostic reports
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and an import permit, if applicable.

Is Beyonttra available in India?

Beyonttra (acoramidis tablets) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of current publicly available information, Beyonttra is not commercially marketed in India.

However, patients in India can legally access Beyonttra through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:
Availability of Beyonttra in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it

• Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  Beyonttra price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada, Europe, and Australia
  Ensuring full transparency throughout the process

Beyonttra can be made available to patients, doctors, and hospitals in Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others— and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only after receipt of a valid doctor’s prescription and an import permit, where applicable.

Indian Pharma Network (IPN) can source Beyonttra from reliable channels across the world and facilitate supply to patients, doctors, and hospitals, offering worldwide access to this treatment under applicable legal provisions. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address from New Delhi, India, after legal requirements are fulfilled.

For Beyonttra cost in India and availability, contact IPN at WhatsApp: +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@indianpharmanetwork.in.

Acoramidis has been approved by multiple major regulatory authorities, under the brand name Beyonttra in most markets and as Attruby in the United States:

• United States (FDA): Approved as Attruby in November 2024.
• European Union (European Commission): Approved as Beyonttra in February 2025; commercialized by Bayer.
• Japan (MHLW): Approved in March 2025.
• United Kingdom (MHRA): Approved as Beyonttra in 2025.
• Switzerland and other markets: Acoramidis carries approvals in the U.S., EU, UK, Switzerland, and Japan.
• Brazil (ANVISA): Approved by ANVISA, with commercialization planned for the second half of 2026.

All approvals are based on the Phase 3 ATTRibute-CM study. In that trial, acoramidis demonstrated a 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization at Month 30, and a 50% reduction in the cumulative frequency of cardiovascular hospitalizations.

What is the generic name for the brand drug Beyonttra?

Acoramidis is the generic name for the brand drug Beyonttra.

What condition does Beyonttra treat?

Beyonttra (acoramidis) treats the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults — a progressive heart condition — to reduce cardiovascular death and hospitalization. It is not a cancer medicine; it is a transthyretin stabilizer for a cardiac/rare disease.

Who develops and manufactures Beyonttra?

Beyonttra (acoramidis) is developed by BridgeBio Pharma, Inc. In the European Union and the United Kingdom, it is commercialized by Bayer under a licensing agreement.

Is Beyonttra approved by the FDA?

In the United States, acoramidis is approved under the brand name Attruby, not Beyonttra. Attruby received FDA approval in November 2024.

Is Beyonttra approved in the European Union?

Yes. The European Commission approved Beyonttra in February 2025, following evaluation of the Phase 3 ATTRibute-CM trial data.

What strengths and dosage forms are available?

Beyonttra is available as 356 mg acoramidis tablets for oral administration; the dose is 712 mg (two tablets) twice daily.

What are the most common side effects?

The most commonly reported side effects are abdominal (stomach-area) pain and diarrhea.

How does Beyonttra import in India work?

Beyonttra import in India is possible through the Named Patient Program (NPP) — on behalf of an individual patient with a valid doctor’s prescription. Indian Pharma Network (IPN) helps manage the process, including documentation, approvals, and delivery, so the medicine reaches the patient safely and legally.

Who is a reliable Beyonttra supplier in India?

Indian Pharma Network (IPN) facilitates compliant access to Beyonttra in India through global sourcing channels and structured documentation support for eligible patients in accordance with applicable regulatory provisions.

How much does Beyonttra cost in India?

Beyonttra is not yet approved or marketed in India, but patients can legally access it through the Named Patient Program. Prices may vary over time due to market and regulatory factors. For the latest Beyonttra cost in India, call or WhatsApp +91 98104 69557 or email info@indianpharmanetwork.in.

Can Beyonttra be accessed in SAARC countries?

Yes. In addition to Gulf countries, Beyonttra can be accessed through import provisions such as the Named Patient Program in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). IPN can help facilitate compliant supply where permitted by local regulations.

Is it safe to buy Beyonttra® Tablets online in India?

Yes, one can buy Beyonttra in India from the Indian Pharma Network (IPN), as this medicinal product is not yet registered or available in the country. We can help facilitate the import of Beyonttra® tablets through legal channels.

Can Beyonttra be delivered to my treating hospital?

Yes. IPN can facilitate delivery of Beyonttra to the patient’s treating hospital across major Indian cities, under the Named Patient Program, with a valid doctor’s prescription and import permit where applicable. Leading hospitals include AIIMS Delhi, Sir Ganga Ram Hospital, Medanta – The Medicity, Apollo Hospitals Chennai, Christian Medical College (CMC), PGIMER, Kidwai Memorial Institute of Oncology, Adyar Cancer Institute, Amrita Hospital, Artemis Hospital, Safdarjung Hospital, Kauvery Hospital, Sri Ramachandra Medical Centre, Cytecare Cancer Hospital, MIOT International, SCTIMST, NIMS Hospital, KIMS Hospitals, AIG Hospitals, Bombay Hospital, Lilavati Hospital, Care Hospitals, Narayana Health City, Jaslok Hospital, Yashoda Hospitals, Fortis Memorial Research Institute, Kokilaben Dhirubhai Ambani Hospital, P. D. Hinduja Hospital, Manipal Hospitals, Aster Medcity, Indraprastha Apollo Hospital, King George’s Medical University (KGMU), Shalby Hospitals, Tata Memorial Centre, HCG Cancer Center, Basavatarakam Indo-American Cancer Hospital, Cancer Institute (WIA), Max Healthcare, and Rajiv Gandhi Cancer Institute & Research Centre.

What are the storage conditions for Beyonttra tablets?

Store at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). Keep in the original blister card until use to protect from moisture.

Disclaimer: Beyonttra® (acoramidis tablets) is a prescription medicine and should only be used under the supervision of a qualified healthcare professional. Product availability, import requirements, and access pathways may vary depending on country-specific regulations.